TESA/IPA Blend 10/1mg

Tesa / Ipamorelin Blend – 10 mg / 1 mg Lyophilized Vial

Chemical Information:

• Tesa Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

• Tesa Molecular Weight: 5135.9 g/mol

• Ipamorelin Molecular Formula: C₃₈H₄₉N₉O₅

• Ipamorelin Molecular Weight: 711.86 g/mol

• Formulation Type: Lyophilized powder blend for reconstitution

Description:
This research blend combines Tesa, a potent Growth Hormone-Releasing Hormone (GHRH) analog, with Ipamorelin, a selective Growth Hormone Secretagogue Receptor (GHSR) agonist. The combination is designed for synergistic study of pulsatile growth hormone release and IGF-1 modulation in experimental settings.

Tesamorelin acts primarily at the pituitary level to stimulate natural growth hormone production via GHRH receptor activation, while Ipamorelin selectively stimulates ghrelin receptors to complement and enhance GH release without significantly affecting cortisol or prolactin.

Research Applications:
The Tesa / Ipamorelin blend is studied for its potential to:

• Enhance Growth Hormone Secretion through dual-pathway stimulation

• Investigate Synergistic GH & IGF-1 Increases in experimental models

• Study Body Composition Changes, including lean mass support and fat metabolism

• Evaluate Metabolic Effects on glucose handling, lipid profiles, and energy expenditure

• Explore Anti-Aging Mechanisms related to GH-mediated tissue repair and regeneration

Storage and Handling:

• Store lyophilized vials at -20°C until use

• After reconstitution, store at 2–8°C and use promptly

• Avoid repeated freeze-thaw cycles

• Use aseptic techniques during reconstitution and withdrawal

Product Specifications:

• Form: Lyophilized powder blend

• Concentration: 10 mg Tesa + 1 mg Ipamorelin per vial

• Purity: ≥99% (HPLC Verified) for each peptide

• Appearance: White lyophilized powder

• Solubility: Soluble in bacteriostatic water for research purposes

Important Note:
For Research Use Only – Not for Human or Veterinary Use
This product is intended solely for in vitro research and laboratory use by qualified professionals. It is not a drug, food, or dietary supplement and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Any bodily administration to humans or animals is strictly prohibited and may violate applicable laws.

References:

• Falutz, J., et al. (2010). “Effects of Tesamorelin on Abdominal Fat and IGF-1 Levels in HIV-Infected Patients with Lipodystrophy.” J Clin Endocrinol Metab

• Raun, K., et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol

• Perry, J., et al. (2020). “Synergistic Effects of GHRH Analogues and GHSR Agonists on GH Release.” Growth Horm IGF Res